High activities of NFκB, TGFβ and JAK-STAT3 pathways prior to treatment were predictive for resistance to anti-TNFα treatment in patients with colon-localized IBD, but not in ileal CD. This evidence concerns the gene TGFB1 and inflammatory bowel disease.